C3N-01416
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 67.18685832
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.520
- CHOLESTEROL_HOMEOSTASIS+0.430
- IL6_JAK_STAT3_SIGNALING+0.380
- COMPLEMENT+0.370
- ALLOGRAFT_REJECTION+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- PROTEIN_SECRETION+0.320
- INFLAMMATORY_RESPONSE+0.310
- APOPTOSIS+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.410
- PANCREAS_BETA_CELLS-0.220
- MYC_TARGETS_V1-0.190
- UNFOLDED_PROTEIN_RESPONSE-0.190
- HEDGEHOG_SIGNALING-0.150
- SPERMATOGENESIS-0.140
- WNT_BETA_CATENIN_SIGNALING-0.140
- KRAS_SIGNALING_DN-0.130
- ESTROGEN_RESPONSE_EARLY-0.100
- GLYCOLYSIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.841 |
| 2 | TCGA-E9-A1QZ-01A-21R-A169-07 | — | A | 0.837 |
| 3 | SRR934945 | — | — | 0.818 |
| 4 | BS_HQ5BJ6MW | pilocytic astrocytoma | — | 0.814 |
| 5 | SRR934924 | — | — | 0.808 |
| 6 | BS_M9C4RY4P | Schwannoma | — | 0.808 |
| 7 | SRR934811 | — | — | 0.807 |
| 8 | f62519fa-7479-4e20-9ae4-d57f8a1e0e64 | — | — | 0.806 |
| 9 | s0112287 | — | — | 0.803 |
| 10 | SRR934884 | — | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |